2017 / 05

Next Paper
DOI: 10.24075/brsmu.2017-05-01

REVIEW

Immunological memory as a basis for a wise vaccination strategy. A rationale for introducing a comprehensive seroepidemiological surveillance system in Russia

Gushchin VA1, Manuilov VA1,3, Mazunina EP1, Kleymenov DA1, Semenenko TA4, Gintsburg AL, Tkachuk AP1
About authors

1 Laboratory of Translational Biomedicine,
N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology, Moscow, Russia

2 Department of Virology, Faculty of Biology,
Lomonosov Moscow State University, Moscow

3 Institute of Molecular Medicine,
I. M. Sechenov First Moscow State Medical University, Moscow, Russia

4 Department of Epidemiology,
N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology, Moscow, Russia

5 N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology, Moscow

Correspondence should be addressed: Vladimir A. Gushchin
ul. Gamalei, d. 18, Moscow, Russia, 123098; moc.liamg@adainawow

About paper

Funding: this paper was prepared with support of the Russian Ministry of Education and Science, project no. RFMEFI60117X0018.

All authors' contribution to this work is equal: selection and analysis of literature, planning of the manuscript's structure, data interpretation, drafting of the manuscript, editing.

Received: 2017-09-24 Accepted: 2017-10-10 Published online: 2017-12-11
|
  1. Sheerin D, Openshaw PJ, Pollard AJ. Issues in vaccinology: Present challenges and future directions. Eur J Immunol. 2017 Sep 1. DOI: 10.1002/eji.201746942.
  2. World Health Organization [Internet]. Geneva, Switzerland: c2017– [cited 2017 Sep] The top 10 causes of death. Fact sheet 2015. Available from: http://www.who.int/mediacentre/factsheets/fs310/ru/index1.html
  3. World Health Organization. Global Tuberculosis Report 2016. 21th ed. France: World Health Organisation; 2016. Available from: http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf
  4. who.int [Internet]. Geneva, Switzerland: World Health Organization; с2017– [cited 2017 Sep]. Available from: http://www.who.int/ru/
  5. van der Klis FR, Mollema L, Berbers GA, de Melker HE, Coutinho RA. Second national serum bank for population-based seroprevalence studies in the Netherlands. Neth J Med. 2009; Jul-Aug; 67 (7): 301–8.
  6. De Melker HE, Conyn-Van Spaendonck MAE. Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. Epidemiol Infect. 1998; 121 (3): 637–43. DOI: 10.1017/S0950268898001587.
  7. Cesaro S, Giacchino M, Fioredda F, Barone A, Battisti L, Bezzio S et al. Guidelines on vaccinations in paediatric haematology and oncology patients. Biomed Res Int. 2014: 707691. DOI: 10.1155/2014/707691.
  8. Xu GJ, Kula T, Xu Q, Li MZ, Vernon SD, Ndung’u T et al. Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. Science. 2015 Jun 5; 348 (6239): aaa0698. DOI: 10.1126/science.aaa0698.
  9. Wolfe RM. Update on adult immunizations. J Am Board Fam Med. 2012 Jul-Aug; 25(4): 496–510. DOI: 10.3122/jabfm.2012.04.100274.
  10. Fine P, Eames K, Heymann DL. "Herd immunity": A rough guide. Clin Infect Dis. 2011 Apr1; 52 (7): 911–6. DOI: 10.1093/cid/cir007.
  11. Martin V, Bryan Wu YC, Kipling D, Dunn-Walters D. Ageing of the B-cell repertoire. Philos Trans R Soc Lond B Biol Sci. 2015 Sep 5; 370 (1676). pii: 20140237. DOI: 10.1098/rstb.2014.0237.
  12. Chao DL, Dimitrov DT. Seasonality and the effectiveness of mass vaccination. Math Biosci Eng. 2016 Apr 1; 13 (2): 249–59. DOI: 10.3934/mbe.2015001.
  13. Wilson SE, Deeks SL, Hatchette TF, Crowcroft NS. The role of seroepidemiology in the comprehensive surveillance of vaccine-preventable diseases. CMAJ. 2012 Jan 10; 184 (1): E70–6. DOI: 10.1503/cmaj.110506.
  14. Kotok A. Besposhchadnaya immunizatsiya. Moscow: Izd-vo «Gomeopaticheskaya Meditsina»; 2004. 448 p. Russian.
  15. Mikhail Gel'fand. V voprose vaktsinatsii gosudarstvo dolzhno vesti sebya kak prosveshchennyy diktator. Snob [Internet]. 2017 Sep 19. Available from: https://snob.ru/selected/entry/129150?utm_source=push&utm_medium=push_notification&utm_campaign=breaking&utm_content=article
  16. Mats AN. [Information for physicians of the anti-vaccination movement and its myth in mass media]. Pediatric Pharmacology. 2009; 6 (6): 12–35. Russian.
  17. World Health Organization [Internet]. Geneva, Switzerland: c2017– [cited 2017 Sep]. Questions and answers on immunization and vaccine safety. Online Q&A. 2016 March. Available from: http://www.who.int/features/qa/84/ru/. Russian.
  18. Bocquier A, Ward J, Raude J, Peretti-Watel P, Verger P. Socioeconomic differences in childhood vaccination in developed countries: a systematic review of quantitative studies. Expert Rev Vaccines. 2017. DOI: 10.1080/14760584.2017.1381020. Epub 2017 Sep 21.
  19. Schoeppe J, Cheadle A, Melton M, Faubion T, Miller C, Matthys J et al. The Immunity Community: A Community Engagement Strategy for Reducing Vaccine Hesitancy. Health Promot Pract. 2017 Sep; 18 (5): 654–61. DOI: 10.1177/1524839917697303.
  20. Caboré RN, Piérard D, Huygen K. A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex. Vaccines (Basel). 2016 May 10; 4 (2). pii: E16. DOI: 10.3390/vaccines4020016.
  21. Metcalf CJ, Farrar J, Cutts FT, Basta NE, Graham AL, Lessler J et al. Use of serological surveys to generate key insights into the changing global landscape of infectious disease. Lancet. 2016 Aug 13; 388 (10045): 728–30. DOI: 10.1016/S0140-6736(16)30164-7.
  22. Giammanco A, Chiarini A, Stroffolini T, De Mattia D, Chiaramonte M, Moschen ME, et al. Seroepidemiology of pertussis in Italy. Rev Infect Dis. 1991 Nov-Dec; 13 (6): 1216–20.
  23. Osnovy gosudarstvennoy politiki v oblasti obespecheniya khimicheskoy i biologicheskoy bezopasnosti Rossiyskoy Federatsii na period do 2025 goda i dal'neyshuyu perspektivu (approves by the President of the Russian Federation, 2013 Nov 1, no. Pr-2573). Russian.
  24. Decree of the Government of the Russian Federation from 15.12.2014 no. 2561-r “Ob utverzhdenii kontseptsii federal'noy tselevoy programmy “Natsional'naya sistema khimicheskoy i biologicheskoy bezopasnosti Rossiyskoy Federatsii (2015–2020 gody)”. Russian.
  25. Fletcher R, Fletcher S, Vagner E. Klinicheskaya epidemiologiya: Osnovy dokazatel'noy meditsiny. Moscow: Media-Sfera; 1998. 346 p. Russian.
  26. Pokrovskiy VI, Briko NI. Epidemiologiya. Uchebnik. Moscow: GEOTAR-Media; 2016. 368 p. Russian.
  27. Order of the Federal Agency of Statistics of the Russian Federation from 28.01.2014 no. 52 “Ob utverzhdenii statisticheskogo instrumentariya dlya organizatsii Federal'noy sluzhboy po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka federal'nogo statisticheskogo nablyudeniya za zabolevaemost'yu naseleniya infektsionnymi i parazitarnymi boleznyami i profilakticheskimi privivkami”. Russian.
  28. Order of the Federal Agency of Statistics of the Russian Federation from 16.09.2016 no. 518 “Ob utverzhdenii statisticheskogo instrumentariya dlya organizatsii Federal'noy sluzhboy po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka federal'nogo statisticheskogo nablyudeniya za profilakticheskimi privivkami protiv infektsionnykh zabolevaniy”. Russian.
  29. Federal law from 17.09.1998 no. 157-FZ “Ob immunoprofilaktike infektsionnykh bolezney” (edition from 19.12.2016). Russian.
  30. Order of the Ministry of Health of the Russian Federation from 21.03.2014 no. 125n “Ob utverzhdenii natsional'nogo kalendarya profilakticheskikh privivok i kalendarya profilakticheskikh privivok po epidemicheskim pokazaniyam” (with changes on 13.04.2017). Russian.
  31. Briko NI. [Assessment of immunoprophylaxis quality and efficiency]. Lechashchiy vrach [Internet]. 2012; (10). Available from: https://www.lvrach.ru/2012/10/15435557/. Russian.
  32. Decree of the Government of the Russian Federation from 30.06.2004 № 322 “Ob utverzhdenii Polozheniya o Federal'noy sluzhbe po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka” (edition from 24.01.2017, with supplements). Russian.
  33. Sanitary and Epidemiological Rules SP 3.3.2367-08 “Organizatsiya immunoprofilaktiki infektsionnykh bolezney”. Approved with Decree of the Chief Sanitary Officer of the Russian Federation from 04.06.2008 no. 34. Implemented from 01.09.2008. Russian.
  34. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiyskoy Federatsii v 2016 godu: Gosudarstvennyy doklad. Moscow: Federal'naya sluzhba po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka; 2017. 220 p. Russian.
  35. Tsvirkun OV. Epidemicheskiy protsess kori v razlichnye periody vaktsinoprofilaktiki [dissertation]. Moscow, Russia: Central Research Institute of Epidemiology; 2014. Russian.
  36. Sanitary and Epidemiological Rules SP 3.1.2952-11 “Profilaktika kori, krasnukhi i epidemicheskogo parotita”. Approved with Decree of the Chief Sanitary Officer of the Russian Federation from 28.07.2011 no. 108. Russian.
  37. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps and rubella – vaccine use and strategies for elimination of measles, rubella, and congenital rubella and control of mumps; recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1998 May 22; 47 (RR-8): 1–57.
  38. McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS; Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013 Jun 14; 62 (RR-04): 1–34.
  39. World Health Organization. Europe launches plan for accelerated action to eliminate measles and rubella. Copenhagen, Denmark: WHO Regional Office for Europe; 2013. Available from: http://www.euro.who.int/en/health-topics/communicable-diseases/measles-andrubella/news/news/2013/09/whoeurope-launches-plan-for-accelerated-action-toeliminate-measles-and-rubella
  40. Order of the Ministry of Health of the Russian Federation from 03.06.1996 no. 226/79 “O vvedenii profilakticheskix privivok protiv gepatita V”. Russian.
  41. Order of the Ministry of Health of the Russian Federation from 27.06.2001 no. 229 “O natsional'nom kalendare profilakticheskikh privivok i kalendare profilakticheskikh privivok po epidemicheskim pokazaniyam”. Russian.
  42. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiyskoy Federatsii v 2012 godu: Gosudarstvennyy doklad. Moscow: Federal'naya sluzhba po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka; 2013. 176 p. Russian.
  43. Demograficheskiy ezhegodnik Rossii 2015. Stat. sb. Moscow: Rosstat; 2015. 263 p. Russian.
  44. Povestka soveshchaniya “Ob itogakh realizatsii prioritetnogo natsional'nogo proekta v sfere zdravookhraneniya v 2007 godu i khode realizatsii v 2008 godu” ot 14 iyulya 2008 goda. Protokol celektornogo soveshchaniya u Rukovoditelya Federal'noy sluzhby po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka, Glavnogo gosudarstvennogo sanitarnogo vracha Rossiyskoy Federatsii G. G. Onishchenko. Epidemiologiya i vaktsinoprofilaktika. 2008; 4 (41): 32–4. Russian.
  45. Onishchenko GG, Merkulov IV, Petrov EYu, Zhelobov VE, Shevchuk NA, Seledtsova OV. O khode immunizatsii naseleniya v ramkakh natsional'nogo kalendarya profilakticheskikh privivok. Protokol selektornogo soveshchaniya u rukovoditelya Federal'noy sluzhby po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka (Protokol no. 13 ot 20.07.2010). Russian.
  46. Statisticheskiy uchet i otchetnost' uchrezhdeniy zdravookhraneniya. Moscow: Ministerstvo zdravookhraneniya i sotsial'nogo razvitiya Rossiyskoy Federatsii; 2006. 81 p. Russian.
  47. Form no. 058/u “Ekstrennoe izveshchenie ob infektsionnom zabolevanii, pishchevom, ostrom professional'nom otravlenii, neobychnoy reaktsii na privivku”. Approved with Order of the Ministry of Healths of USSR from 04.10.80 no. 1030 (edition from 31.12.2002) “Ob utverzhdenii form pervichnoy meditsinskoy dokumentatsii uchrezhdeniy zdravookhraneniya”. Russian.
  48. O pravomochnosti deystviya prikaza Minzdrava SSSR ot 4 oktyabrya 1980 goda no. 1030 “Ob utverzhdenii form pervichnoy meditsinskoy dokumentatsii uchrezhdeniy zdravookhraneniya”. Letter of the Ministry of Health and Social Development of the Russian Federation from 30.11.2009 no. 14-6/242888. Russian.
  49. Kishkun AA, Arsenin SL. Osnovnye napravleniya reformirovaniya laboratornoy sluzhby Rossii. Meditsinskiy alfavit. 2011; 4: 4–10. Russian.
  50. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiyskoy Federatsii v 2015 godu: Gosudarstvennyy doklad. Moscow: Federal'naya sluzhba po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka; 2016. 200 p. Russian.
  51. Rolfes MA, Foppa IM, Garg S, Flannery B, Brammer L, Singleton JA et al. Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths Averted by Vaccination in the United States. Centers for Disease Control and Prevention [Internet]. [updated 2017 Apr 19] Available from: https://www.cdc.gov/flu/about/disease/2015-16.htm
  52. Nakamura Y, Sugawara T, Kawanohara H, Ohkusa Y, Kamei M, Oishi K. Evaluation of estimated number of influenza patients from national sentinel surveillance using the national database of electronic medical claims. Jpn J Infect Dis. 2015; 68 (1): 27–9. DOI: 10.7883/yoken.JJID.2014.092.
  53. Murakami Y, Hashimoto S, Kawado M, Ohta A, Taniguchi K, Sunagawa T, et al. Estimated number of patients with influenza A(H1)pdm09, or other viral types, from 2010 to 2014 in Japan. PLoS One. 2016; 11 (1): e0146520. DOI: 10.1371/journal.pone.0146520.
  54. Zaraket H, Saito R. Japanese Surveillance Systems and Treatment for Influenza. Curr Treat Options Infect Dis. 2016; 8 (4): 311–28. DOI: 10.1007/s40506-016-0085-5.
  55. Sanitary and Epidemiological Rules SP 3.1.2.3117-13 “Profilaktika grippa i drugikh ostrykh respiratornykh virusnykh infektsiy”. Approved with Decree of the Chief Sanitary Officer of the Russian Federation from 18.11.2013 no. 63. Russian.
  56. Hyams K.C. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995; 20 (4): 992–1000.
  57. Methodic Guide MU 3.1.2792-10 «3.1. Profilaktika infektsionnykh bolezney. Epidemiologicheskiy nadzor za gepatitom B». Approved and implemented by the Chief Sanitary Officer of the Russian Federation from 2010 Dec 20. Russian.
  58. World Health Organization [Internet]. Geneva, Switzerland: c2017– [cited 2017 Sep] Global'naya strategiya sektora zdravookhraneniya po virusnomu gepatitu 2016–2021. Na puti k likvidatsii virusnogo gepatita. VOZ, iyun' 2016. Available from: http://apps.who.int/iris/bitstream/10665/250042/1/WHO-HIV-2016.06-rus.pdf. Russian.
  59. Vyazov SO, Kompaniets AA, Anan'ev VA, Listovskaya EK, Dardik FG, Pirozhkova ZP. Vyyavlenie HBsAg anti-HBs u zdorovogo naseleniya razlichnykh gorodov SSSR. Voprosy virusologii. 1985; 2: 231–3. Russian.
  60. Somova AV, Golosova TV, Margolina AN, Bagryantseva SYu. Serodiagnostika virusnykh gepatitov C i B sredi razlichnykh grupp naseleniya. Voprosy virusologii. 1992; 4: 105–7. Russian.
  61. Shakhgil'dyan IV, Mikhaylov MI, Onishchenko GG. Parenteral'nye virusnye gepatity (epidemiologiya, diagnostika, profilaktika). Moscow: GOU VUNMTs; 2003. 384 p. Russian.
  62. Manuilov VA, Osipova LP, Netesova IG, Chub EV, Bezuglova LV, Norder H et al. [Prevalence of HBsAg and genotypes of native population groups of Siberia]. Molekulyarnaya genetika, mikrobiologiya i virusologiya. 2015; 1: 28–35. Russian.
  63. Ray Kim W. Epidemiology of Hepatitis B in the United States. Hepatology. 2009; 49 (5): 28–34.
  64. International Classifications of Diseases, 10th Revision, 1989. Recommended for use in the Russian Federation with instruction “Instruktsiya po ispol'zovaniyu Mezhdunarodnoy statisticheskoy klassifikatsii bolezney i problem, svyazannykh so zdorov'em, desyatogo peresmotra (dlya pol'zuyushchegosya MKB-10)” (approved by the Ministry of Health of the Russian Federation from 25.05.1998 no. 2000/52-98). Russian.
  65. Rukovodstvo po kodirovaniyu prichin smerti. Moscow: TsNIIOIZ; 2008. 74 p. Russian.
  66. Order of the Ministry of Health of the Russian Federation from 21.03.2003 no. 117 "O realizatsii "Programmy likvidatsii kori v rossiyskoy federatsii k 2010 godu" (s prilozheniyami). Russian.
  67. Petrovskiy BV. Entsiklopedicheskiy slovar' meditsinskikh terminov. Moscow: Izd-vo “Sovetskaya Entsiklopediya”; 1984. 1591 p. Russian.
  68. Methodic Guide MU 3.1.2943-11 “Organizatsiya i provedenie serologicheskogo monitoringa sostoyaniya kollektivnogo immuniteta k infektsiyam, upravlyaemym sredstvami spetsificheskoy profilaktiki (difteriya, stolbnyak, koklyush, kor', krasnukha, epidemicheskiy parotit, poliomielit, gepatit B)”. Approved and implemented by the Chief Sanitary Officer of the Russian Federation from 15.07.2011. Russian.
  69. Odland JO, Sergejeva IV, Ivaneev MD, Jensen IP, Stray-Pedersen B. Seropositivity of cytomegalovirus, parvovirus and rubella in pregnant women and recurrent aborters in Leningrad County, Russia. Acta Obstet Gynecol Scand. 2001 Nov; 80 (11): 1025–9.
  70. Grigor'eva TD, Belopol'skaya MA, Vashukova SS, Makarova NG, Andreeva NV. [Features of laboratory tests for diagnosis of rubella in pregnant women]. Zhurnal infektologii, 2014; 6 (3): 44–50. Russian.
  71. Agafonov AP, editor. Epidemicheskiy parotit. Sovremennye predstavleniya o vozbuditele, klinika, diagnostika, profilaktika. Novosibirsk: Mediko-biologicheskiy Soyuz; 2007. 82 p. Russian.
  72. Otrashevskaya EV, Krasil'nikov IV, Ignat'ev GM. [Investigation of genotype-specific serum neutralizing activity in children and adolescents immunized with Russian mumps vaccine]. Voprosy virusologii. 2010; 55 (6):15–9. Russian.
  73. Kontarova E.O. Effektivnost' vaktsinoprofilaktiki epidemicheskogo parotita na ryade territoriy Rossiyskoy Federatsii [dissertatsiya]. Moscow, Russia: Chumakov Research Center for Poliomyelitis and Viral Encephalitis; 2013. Russian.
  74. Mukomolov SL, Bolsun DD, Krasnyakov VK, Levakova IA, Gribanov AYu et al. [Frequency of antibodies against surface and nuclear antigens of hepatitis B virus in population of St. Petersburg in 2013]. Journal of Microbiology, Epidemiology and Immunobiology. 2014; 5: 43–9. Russian.
  75. Netesova IG, Swenson PD, Osipova LP, Gubina MA, Posukh OL, Netesov SV. Determination of HBsAg subtypes in Western Siberian part of Russia. J Med Virol. 2003; 71: 183–7.
  76. Manuilov VA, Netesova IG, Osipova LP, Shustov AV, Bayandin RB, Kochneva GV et al. [Genetic variability of hepatitis B virus isolates among population of Shuryshkarsky district of Yamal-Nenets autonomous region]. Molekulyarnaya genetika, mikrobiologiya i virusologiya. 2005; 4: 30-34. Russian.
  77. Semenenko TA, Zubkin ML, Yarosh LV, Chervinko VI, Frolova NF, Suslov AP. [Latent hepatitis B and mutant forms hepatitis B virus in kidney transplant recipients with chronic liver diseases]. 2016; 14 (3): 6–13. DOI: 10.20953/1729-9225-2016-3-6-13. Russian.
  78. Centers for Disease Control Prevention (CDC) [Internet]. Atlanta, GA: CDC [cited 2017 Sep]. Immunization Information Systems (IIS). Available from: https://www.cdc.gov/vaccines/programs/iis/index.html
  79. Derrough T, Olsson K, Gianfredi V, Simondon F, Heibel H, Danielsson N, et.al. Immunisation Information Systems – useful tools for monitoring vaccination programmes in EU/EEA countries, 2016. Euro Surveill. 2017; 22 (17): 5–15. DOI: 10.2807/1560-7917.ES.2017.22.17.30519.
  80. World Health Organisation. European Vaccine Action Plan 2015–2020. Geneva, Switzerland: WHO [cites 2017 Sep]. Available from: http://www.euro.who.int/__data/assets/pdf_file/0007/255679/WHO_EVAP_UK_v30_WEBx.pdf?ua=1
  81. Karimi-Busheri F. editor. Biobanking in the 21st Century. Advances in Experimental Medicine and Biology 864. Springer; 2015. DOI: 10.1007/978-3-319-20579-3.
  82. Van den Hof S, de Melker HE, Berbers GA, der Kraak PH, Spaendonck MA. Antibodies to Haemophilus influenzae serotype b in the Netherlands a few years after the introduction of routine vaccination. Clin Infect Dis. 2001 Jan; 32 (1): 2–8. DOI: 10.1086/317538.
  83. de Melker HE, van den Hof S, Berbers GA, Conyn-van Spaendonck MA. Evaluation of the national immunisation programme in the Netherlands: immunity to diphtheria, tetanus, poliomyelitis, measles, mumps, rubella and Haemophilus influenzae type b. Vaccine. 2003 Jan 30; 21 (7–8): 716–20.
  84. Veldhuijzen IK, Conyn-van Spaendonck MA, Dorigo-Zetsma JW. Seroprevalentie van hepatitis B en C in de Nederlandse bevolking. Infectieziekten Bull. 1999; 10: 182–4.
  85. Termorshuizen F, Dorigo-Zetsma JW, de Melker HE, van den Hof S, Conyn-van Spaendonck MA. The prevalence of antibodies to hepatitis A virus and its determinants in The Netherlands: a population-based survey. Epidemiol Infect. 2000 Jun; 124 (3): 459–66.
  86. Kortbeek LM, de Melker HE, Veldhuijzen IK, Conyn-van Spaendonck MA. Population-based Toxoplasma seroprevalence study in The Netherlands. Epidemiol Infect. 2004 Oct; 132 (5): 839–45.
  87. Mollema L, de Melker HE, Hahné SJM, van Weert JWM, Berbers GAM, van der Klis FRM. PIENTER 2-project: second research project on the protection against infectious diseases offered by the national immunization programme in the Netherlands. RIVM report 230421001/2009. Bilthoven, the Netherlands: RIVM; 2009.
  88. Theeten H, Hutse V, Hens N, Yavuz Y, Hoppenbrouwers K, Beutels P, et al. Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium. Epidemiol Infect. 2011 Apr; 139 (4): 494–504. DOI: 10.1017/S0950268810001536.
  89. Huygen K, Rodeghiero C, Govaerts D, Leroux-Roels I, Melin P, Reynders M, et al. Bordetella pertussis seroprevalence in Belgian adults aged 20–39 years, 2012. Epidemiol Infect. 2014 Apr; 142 (4): 724–8. DOI: 10.1017/S0950268813002458.
  90. Moriuchi T, Otsuka N, Hiramatsu Y, Shibayama K, Kamachi K. A high seroprevalence of antibodies to pertussis toxin among Japanese adults: Qualitative and quantitative analyses. PLoS ONE. 2017 12 (7): e0181181. DOI: 10.1371/journal.pone.0181181.
  91. Alsuwaidi AR, Al-Mekaini LA, Kamal SM, Narchi H, Souid AK. Seroprevalence of influenza A and B viruses among unvaccinated children in the United Arab Emirates: a cross-sectional study. BMC Res Notes. 2017 Aug 10; 10 (1): 379. DOI: 10.1186/s13104-017-2720-8.
  92. Al-Mekaini LA, Kamal SM, Al-Jabri O, Soliman M, Alshamsi H, Narchi H et al. Seroprevalence of vaccine-preventable diseases among young children in the United Arab Emirates. Int J Infect Dis. 2016 Sep; 50: 67–71. DOI: 10.1016/j.ijid.2016.07.012.
  93. Bassal R, Weil M, Cohen D, Sofer D, Mendelson E, Shohat T. Seroprevalence of Hepatitis A Twelve Years After the Implementation of Toddlers' Vaccination: A Population-Based Study in Israel. Pediatr Infect Dis J. 2017 Oct; 36 (10): e248–e251. DOI: 10.1097/INF.0000000000001640.
  94. Alfonso VH, Doshi RH, Mukadi P, Higgins SG, Hoff NA, Bwaka A et al. Prevalence of Rubella Antibodies Among Children in the Democratic Republic of the Congo. Pediatr Infect Dis J. 2017 Jul 19. DOI: 10.1097/INF.0000000000001703.
  95. Alberts CJ, Michel A, Bruisten S, Snijder MB, Prins M, Waterboer T et al. High-risk human papillomavirus seroprevalence in men and women of six different ethnicities in Amsterdam, the Netherlands: The HELIUS study. Papillomavirus Res. 2017 Jun; 3: 57–65. DOI: 10.1016/j.pvr.2017.01.003.
  96. Palazzo R, Carollo M, Fedele G, Rizzo C, Rota MC, Giammanco A et al. Evidence of increased circulation of Bordetella pertussis in the Italian adult population from seroprevalence data (2012–2013). J Med Microbiol. 2016 Apr 13; 65: 649–57. DOI: 10.1099/jmm.0.000264.
  97. Getahun M, Beyene B, Gallagher K, Ademe A, Teshome B, Tefera M et al. Epidemiology of rubella virus cases in the pre-vaccination era of Ethiopia, 2009–2015. BMC Public Health. 2016 Nov 18; 16 (1): 1168. DOI: 10.1186/s12889-016-3841-z.
  98. Mayorga O, Bühler S, Jaeger VK, Bally S, Hatz C, Frösner G et al. Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response. J Infect Dis. 2016 Nov 15; 214 (10): 1498–1506. DOI: 10.1093/infdis/jiw411.
  99. Scobie HM, Mao B, Buth S, Wannemuehler KA, Sørensen C, Kannarath C et al. Tetanus Immunity among Women Aged 15 to 39 Years in Cambodia: a National Population-Based Serosurvey, 2012. Clin Vaccine Immunol. 2016 Jul 5; 23 (7): 546–54. DOI: 10.1128/CVI.00052-16.
  100. Swart EM, van Gageldonk PG, de Melker HE, van der Klis FR, Berbers GA, Mollema L. Long-Term Protection against Diphtheria in the Netherlands after 50 Years of Vaccination: Results from a Seroepidemiological Study. PLoS One. 2016 Feb 10; 11 (2): e0148605. DOI: 10.1371/journal.pone.0148605.
  101. Li X, Chen M, Zhang T, Li J, Zeng Y, Lu L. Seroepidemiology of diphtheria and pertussis in Beijing, China: A cross-sectional study. Hum Vaccin Immunother. 2015; 11 (10): 2434–9. DOI: 10.1080/21645515.2015.1062954.
  102. Yonghao G, Jin X, Jun L, Pumei D, Ying Y, Xiuhong F et al. An epidemiological serosurvey of hepatitis B virus shows evidence of declining prevalence due to hepatitis B vaccination in central China. Int J Infect Dis. 2015 Nov; 40: 75–80. DOI: 10.1016/j.ijid.2015.10.002.
  103. Reynolds MA, Kruszon-Moran D, Jumaan A, Schmid DS, McQuillan GM. Varicella seroprevalence in the U.S.: data from the National Health and Nutrition Examination Survey, 1999–2004. Public Health Rep. 2010 Nov-Dec; 125 (6): 860–9. DOI: 10.1177/003335491012500613.
  104. Lessler J, Metcalf CJE, Cutts FT, Grenfell BT. Impact on Epidemic Measles of Vaccination Campaigns Triggered by Disease Outbreaks or Serosurveys: A Modeling Study. PLoS Med. 2016; 13: 1–14. DOI: 10.1371/journal.pmed.1002144.
  105. Edmunds WJ1, Pebody RG, Aggerback H, Baron S, Berbers G, Conyn-van Spaendonck MA et al. The seroepidemiology of diphtheria in western Europe. ESEN Project. European Sero-Epidemiology Network. Epidemiol Infect. 2000; 125: 113–25.
  106. Ramsay M1, Gay N, Miller E, Rush M, White J, Morgan-Capner P et al. The epidemiology of measles in England and Wales: rationale for the 1994 national vaccination campaign. Commun Dis Rep CDR Rev. 1994 Nov 11; 4 (12): R141–6.
  107. Gay NJ, Hesketh LM, Morgan-Capner P, Miller E. Interpretation of serological surveillance data for measles using mathematical models: implications for vaccine strategy. Epidemiol Infect. 1995; 115 (1): 139–56.
  108. Osborne K1, Gay N, Hesketh L, Morgan-Capner P, Miller E. Ten years of serological surveillance in England and Wales: methods, results, implications and action. Int J Epidemiol. 2000; 29: 362–8.
  109. Gilbert GL1, Escott RG, Gidding HF, Turnbull FM, Heath TC, McIntyre PB et al. Impact of the Australian Measles Control Campaign on immunity to measles and rubella. Epidemiol Infect. 2001; 127: 297–303.
  110. Campbell M. Young adult measles vaccination. Commun Dis Intell. 2000 Aug; 24 (8): 241–2.
  111. De Melker HE, van Lier EH. The National Immunisation Programme in the Netherlands; developments in 2008. RIVM report 210021009/2009. Bilthoven, the Netherlands: RIVM; 2009.
  112. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis. 2009 Oct 1; 200 (7): 1059–67. DOI: 10.1086/604729.
  113. Diedrich S, Weinbrecht A, Schreier E. Seroprevalence and molecular epidemiology of enterovirus 71 in Germany. Arch Virol. 2009; 154 (7): 1139–42. DOI: 10.1007/s00705-009-0413-x.
  114. Prins-Van Ginkel AC, Berbers GAM, Grundeken LH, Tcherniaeva I, Wittenberns JI, Elberse K et al. Dynamics and determinants of pneumococcal antibodies specific against 13 vaccine serotypes in the pre-vaccination era. PLoS One. 2016 Jan 21. DOI: 10.1371/journal.pone.0147437.
  115. Smits GP, Van Gageldonk PG, Schouls LM, Van der Klis FRM, Berbers GAM. Development of a bead-based multiplex immunoassay for simultaneous quantitative detection of IgG serum antibodies against measles, mumps, rubella, and varicella-zoster virus. Clin. Vaccine Immunol. 2012; 19 (3): 396–400. DOI: 10.1128/CVI.05537-11.
  116. Lal G, Balmer P, Stanford E, Martin S, Warrington R, Borrow R. Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J Immunol Methods. 2005 Jan; 296 (1–2): 135–47. DOI: 10.1016/j.jim.2004.11.006.
  117. Luminexcorp.com [Internet]. Luminex Corporation; c2006–2017 [cited 2017 Sep]. The xMAP cookbook. 3rd ed. Available from: http://info.luminexcorp.com/en-us/download-the-xmap-cookbook
  118. Biagini RE, Schlottmann SA, Sammons DL, Smith JP, Snawder JC, Striley CA et al. Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides. Clin Diagn Lab Immunol. 2003 Sep; 10 (5): 744–50.
  119. Wild D, editor. The immunoassay handbook.4th ed. Elsevier; 2013.
  120. van Gageldonk PG, van Schaijk FG, van der Klis FR, Berbers GA. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods. 2008 Jun 1; 335 (1–2): 79–89. DOI: 10.1016/j.jim.2008.02.018.
  121. Pickering JW, Martins TB, Greer RW, Schroder MC, Astill ME, Litwin CM et al. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. Am J Clin Pathol. 2002 Apr; 117 (4): 589–96. DOI: 10.1309/4KEH-AGY7-UT5H-41XJ.
  122. Pickering JW, Martins TB, Schroder MC, Hill HR. Comparison of a multiplex flow cytometric assay with enzyme-linked immunosorbent assay for quantitation of antibodies to tetanus, diphtheria, and Haemophilus influenzae type b. Clin Diagn Lab Immunol. 2002 Jul; 9 (4): 872–6. DOI: 10.1128/CDLI.9.4.872-876.2002.
  123. Elberse KE, Tcherniaeva I, Berbers GA, Schouls LM. Optimization and application of a multiplex bead-based assay to quantify serotype-specific IgG against Streptococcus pneumoniae polysaccharides: response to the booster vaccine after immunization with the pneumococcal 7-valent conjugate vaccine. Clin Vaccine Immunol. 2010 Apr; 17 (4): 674–82. DOI: 10.1128/CVI.00408-09.
  124. Brodin P, Davis MM. Human immune system variation. Nat Rev Immunol. 2017; 17: 21–9. DOI: 10.1038/nri.2016.125.
  125. Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis. 2008 Apr 1; 46 (7): 1078–84. DOI: 10.1086/529197.
  126. Gibson KL, Wu YC, Barnett Y, Duggan O, Vaughan R, Kondeatis E et al. B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell. 2009 Feb; 8 (1): 18–25. DOI: 10.1111/j.1474-9726.2008.00443.x.
  127. Britanova OV, Shugay M, Merzlyak EM, Staroverov DB, Putintseva EV, Turchaninova MA et al. Dynamics of Individual T Cell Repertoires: From Cord Blood to Centenarians. J Immunol. 2016 Jun 15; 196 (12): 5005–13. DOI: 10.4049/jimmunol.1600005.
  128. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002 Nov; 2 (11): 659–66. DOI: 10.1016/S1473-3099(02)00437-1.
  129. Ahmed M, Lanzer KG, Yager EJ, Adams PS, Johnson LL, Blackman MA. Clonal expansions and loss of receptor diversity in the naive CD8 T cell repertoire of aged mice. J Immunol. 2009 Jan 15; 182 (2): 784–92.
  130. Chen WH, Kozlovsky BF, Effros RB, Grubeck-Loebenstein B, Edelman R, Sztein MB. Vaccination in the elderly: an immunological perspective. Trends Immunol. 2009 Jul; 30 (7): 351–9. DOI: 10.1016/j.it.2009.05.002.
  131. Chen TH, Lee F, Lin YL, Dekker A, Chung WB, Pan CH et at. Differentiation of foot-and-mouth disease-infected pigs from vaccinated pigs using antibody-detecting sandwich ELISA. J Vet Med Sci. 2011 Aug; 73 (8): 977–84.
  132. Hollinger FB, Liang TJ. Hepatitis B virus. In: Knipe DM, Howley PM, Griffin DE, Martin MA, Lamb RA, Roizman B. Fields Virology. Vol. 4. Philadelphia: Lippincott-Raven Publishers; 2001.
  133. Qiu J, Wang W, Wu J, Zhang H, Wang Y, Qiao J. Characterization of periplasmic protein BP26 epitopes of Brucella melitensis reacting with murine monoclonal and sheep antibodies. PLoS One. 2012; 7 (3): e34246. DOI: 10.1371/journal.pone.0034246.
  134. Tkachuk AP, Gushchin VA, Potapov VD, Demidenko AV, Lunin VG, Gintsburg AL. Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models. Cardona P-J, ed. PLoS ONE. 2017; 12 (4): e0176784. DOI: 10.1371/journal.pone.0176784.
  135. Carter MJ, Mitchell RM, Sauteur PMM, Kelly DF, Trück J. The antibody-secreting cell response to infection: Kinetics and clinical applications. Front Immunol. 2017 Jun 1; 8: 630. DOI: 10.3389/fimmu.2017.00630.
  136. Whitworth HS, Scott M, Connell DW, Dongés B, Lalvani A. IGRAs--the gateway to T cell based TB diagnosis. Methods. 2013 May 15; 61 (1): 52–62. DOI: 10.1016/j.ymeth.2012.12.012.
  137. Huo Z, Peng L. Accuracy of the interferon-γ release assay for the diagnosis of active tuberculosis among HIV-seropositive individuals: a systematic review and meta-analysis. BMC Infect Dis. 2016 Jul 22; 16: 350. DOI: 10.1186/s12879-016-1687.
  138. Chattopadhyay PK, Roederer M. A mine is a terrible thing to waste: high content, single cell technologies for comprehensive immune analysis. Am J Transplant. 2015 May; 15 (5): 1155–61. DOI: 10.1111/ajt.13193.
  139. Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res. 2011 Aug; 39 (15): e102. DOI: 10.1093/nar/gkr424.
  140. Frei AP, Bava FA, Zunder ER, Hsieh EW, Chen SY, Nolan GP et al. Highly multiplexed simultaneous detection of RNAs and proteins in single cells. Nat Methods. 2016 Mar; 13 (3): 269–75. DOI: 10.1038/nmeth.3742.
  141. Semenenko TA. [The role of blood serum bank in the national biological safety]. Vestnik Roszdravnadzora. 2010; (3): 55–8. Russian.
  142. Sanitary and Epidemiological Rules SP 1.3.2322-08 “Bezopasnost' raboty s mikroorganizmami III–IV grupp patogennosti (opasnosti) i vozbuditelyami parazitarnykh bolezney. Sanitarno-epidemiologicheskie pravila”. Approved with Decree of the Chief Sanitary Officer of the Russian Federation from 28.01.2008 no 4. Russian.
  143. Methodic Guide MU 1.3.2569-09 “Organizatsiya raboty laboratoriy, ispol'zuyushchikh metody amplifikatsii nukleinovykh kislot pri rabote s materialom, soderzhashchim mikroorganizmy I–IV grupp patogennosti. Metodicheskie ukazaniya”. Moscow: Rospotrebnadzor; 2009. 42 p. Russian.
  144. Glants S. Mediko-biologicheskaya statistika. Moscow: Praktika; 1999. 462 p. Russian.
  145. Fel'dblyum IV. [Prophylactic vaccination as life-saving technology and a tool of demographic policy]. Epidemiologiya i infektsionnye bolezni. Aktual'nye voprosy. 2011; 2: 12–7. Russian.
  146. Semenenko TA, Rusakova EV, Shcherbakov AG, Gaidarenko AD, Gotvyanskaya TP, Evseyeva LF et al. [Herd immunity against controlled infections (according to the materials of the serum bank)]. Epidemiologiya i infektsionnye bolezni. Aktual'nye voprosy. 2012; 6: 10–5. Russian.
  147. Mollema L, Smits GP, Berbers GA, Van Der Klis FR, Van Binnendijk RS, De Melker HE et al. High risk of a large measles outbreak despite 30 years of measles vaccination in The Netherlands. Epidemiol Infect. 2014 May; 142 (5): 1100–8. DOI: 10.1017/S0950268813001532.
  148. Mroz T, Mancini D, Popkin BM. Monitoring Economic Conditions in the Russian Federation: The Russia Longitudinal Monitoring Survey 1992–1998. Report. Chapel Hill, N. C.: Carolina Population Center; 1999.
  149. Boitsov SA, Chazov EI, Shlykhto EV, Shalnova SA, Konradi AO, Karpov YuA et al. [Epidemiology of cardiovascular diseases in different regions of Russia (ESSE-RF). The rational for and design of the study]. Profilakticheskaya meditsina. 2013; 16 (6): 25–34. Russian.
  150. Centers for Disease Control Prevention (CDC) [Internet]. Atlanta, GA: CDC [cited 2017 Sep]. National Health and Nutrition Examination Survey. Available from: https://www.cdc.gov/nchs/nhanes/index.htm
  151. Wu JT, Ho A, Ma ES, Lee CK, Chu DK, Ho PL et al. Estimating infection attack rates and severity in real time during an influenza pandemic: analysis of serial cross-sectional serologic surveillance data. PLoS Med. 2011 Oct; 8(10): e1001103. doi: 10.1371/journal.pmed.1001103.
  152. WHO. Seroepidemiological studies of pandemic influenza A (H1N1) 2009 virus. Weekly Epidemiologic Record 2010; 24: 229-236. PMID:20545056.
  153. Semenov BF, Zverev VV, Khaitov RM. [Prospects for development of immunoprophylaxis up to 2020–2030]. Zhurnal mikrobiologii, epidemiologii i immunobiologii. 2010; 2: 105–11. Russian.
  154. Shakhanina IL, Raduto OI, Osipova LA, Prikazchikova GS. [Economic efficiency of vaccinal prevention: methods of assessment]. Epidemiologiya i infektsionnye bolezni. 2004; 3: 12–6. Russian.
  155. Methodic Guide MU 3.3.1878-04 “Immunoprofilaktika infektsionnykh bolezney. Ekonomicheskaya effektivnost' vaktsinoprofilaktiki. Metodicheskie ukazaniya”. Approved with Decree of the Chief Sanitary Officer of the Russian Federation from 04.03.2004. Russian.
  156. Bektimirov TA. Ekonomicheskie prioritety vaktsinoprofilaktiki – opyt raznykh stran. Byulleten' “Vaktsinatsiya. Novosti vaktsinoprofilaktiki”. 2000; 1 (7): 14–20. Russian.